Simulect is a Intravenous Injection, Powder, For Solution in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Basiliximab.
Product ID | 0078-0331_0673b70a-a94f-4a8b-8153-1402e33fa3e0 |
NDC | 0078-0331 |
Product Type | Human Prescription Drug |
Proprietary Name | Simulect |
Generic Name | Basiliximab |
Dosage Form | Injection, Powder, For Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 1998-05-12 |
Marketing Category | BLA / BLA |
Application Number | BLA103764 |
Labeler Name | Novartis Pharmaceuticals Corporation |
Substance Name | BASILIXIMAB |
Active Ingredient Strength | 20 mg/5mL |
Pharm Classes | Interleukin 2 Receptor Antagonists [MoA],Interleukin 2 Receptor-directed Antibody Interactions [MoA],Interleukin-2 Receptor Blocking Antibody [EPC] |
NDC Exclude Flag | N |
Listing Certified Through | 2019-12-31 |
Marketing Start Date | 1998-05-12 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA103764 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 1998-05-12 |
Ingredient | Strength |
---|---|
BASILIXIMAB | 20 mg/5mL |
SPL SET ID: | 1af01887-b69d-444b-91ed-ebfe12784440 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0078-0331 | Simulect | basiliximab |
0078-0393 | Simulect | basiliximab |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
SIMULECT 79059709 3639864 Live/Registered |
Novartis AG 2008-09-24 |
SIMULECT 74665427 2122043 Live/Registered |
NOVARTIS AG 1995-04-24 |
SIMULECT 74342122 not registered Dead/Abandoned |
SANDOZ AG (SANDOZ LTD., SANDOZ S.A.) 1992-12-18 |